文献速递系统性红斑狼疮

系统性红斑狼疮维持治疗中吗替麦考酚酯的安全性:日本全国性前瞻性队列LUNA登记研究

Safety of mycophenolate mofetil in systemic lupus erythematosus maintenance therapy: insights from the LUNA registry in a nationwide prospective cohort study.
PubMed 文献 · RMD Open · 2025-07-22

基于日本LUNA全国性前瞻性队列,比较系统性红斑狼疮维持治疗中吗替麦考酚酯(MMF)与其他免疫抑制剂的安全性,共纳入1004例患者。MMF组严重感染发生率为6.5%,非MMF组为7.5%,无显著差异(OR 0.69,95%CI 0.34至1.39)。MMF组泼尼松龙剂量显著降低,器官损害评分轻度降低,疾病活动度评分变化两组相当。

要点

  • MMF组严重感染6.5% vs 非MMF组7.5%,OR 0.69(95%CI 0.34至1.39),无显著差异。
  • MMF组泼尼松龙剂量降低0.66 mg/天(95%CI -1.09至-0.23)。
  • MMF组器官损害评分降低0.19分(95%CI -0.37至-0.01),疾病活动度变化两组相当。

核心结论

  • 与 другие免疫抑制剂相比,MMF未显著增加系统性红斑狼疮维持治疗中严重感染的风险。
  • MMF可能有助于减少泼尼松龙的剂量。

研究设计与样本

  • 研究为前瞻性队列设计,数据来自日本全国性机构狼疮登记(LUNA)。
  • 纳入接受维持治疗的系统性红斑狼疮患者,暴露定义为MMF治疗,对照组为接受其他免疫抑制剂(非MMF)治疗者。
  • 主要结局为需住院治疗的严重感染,次要结局包括全因住院、泼尼松龙剂量变化、疾病活动度和器官损害。
  • 统计分析采用边际结构模型与稳定化逆概率治疗加权调整混杂因素。
  • 分析共纳入1004例患者。

主要发现

  • 严重感染发生率MMF组为6.5%,非MMF组为7.5%,无显著差异(OR 0.69,95%CI 0.34至1.39)。
  • 全因住院率两组相当(OR 0.72,95%CI 0.47至1.09)。
  • 泼尼松龙剂量在MMF组显著降低(-0.66 mg/天,95%CI -1.09至-0.23)。
  • 器官损害评分在MMF组轻度降低(-0.19分,95%CI -0.37至-0.01)。
  • 疾病活动度评分变化两组相当(-0.10分,95%CI -0.74至0.55)。

关键数值与推荐

  • 严重感染:MMF组6.5% vs 非MMF组7.5%,OR 0.69(95%CI 0.34至1.39)。
  • 全因住院:OR 0.72(95%CI 0.47至1.09)。
  • 泼尼松龙剂量变化:MMF组-0.66 mg/天(95%CI -1.09至-0.23)。
  • 器官损害评分变化:MMF组-0.19分(95%CI -0.37至-0.01)。
  • 疾病活动度评分变化:-0.10分(95%CI -0.74至0.55)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We aimed to compare the incidence of severe infections between mycophenolate mofetil (MMF) and other immunosuppressants in patients with systemic lupus erythematosus (SLE) on maintenance therapy using data from the Lupus Registry of Nationwide Institutions in Japan. METHODS: This study employed a prospective cohort design, including patients with SLE undergoing maintenance therapy. Exposure was defined as MMF treatment, and the control group included individuals who received other immunosuppressants (non-MMF) treatments. Severe infections requiring hospitalisation were the primary outcomes, whereas secondary outcomes included all-cause hospitalisation, changes in prednisolone dosage, disease activity and organ damage. Statistical analyses employed marginal structural models with stabilised inverse probability of treatment weighting to adjust for confounders. RESULTS: The analysis included 1004 patients; the incidence of severe infections was 6.5% in the MMF group and 7.5% in the non-MMF group, with no significant difference (OR 0.69, 95% CI 0.34 to 1.39). Similarly, all-cause hospitalisation rates were comparable between the groups (OR 0.72, 95% CI 0.47 to 1.09). Prednisolone dosage was significantly reduced in the MMF group (-0.66 mg/day, 95% CI -1.09 to -0.23). The organ damage score was modestly reduced in the MMF group (-0.19 points, 95% CI -0.37 to -0.01), whereas the change of disease activity score was comparable between the groups (-0.10 points, 95% CI -0.74 to 0.55). CONCLUSIONS: MMF does not significantly increase the risk of severe infections compared with other immunosuppressants in SLE maintenance therapy. MMF may contribute to reducing the dose of prednisolone.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Matsuoka N, Yajima N, Inoue E, et al. Safety of mycophenolate mofetil in systemic lupus erythematosus maintenance therapy: insights from the LUNA registry in a nationwide prospective cohort study. RMD Open. 2025. PMID: 40701623. doi:10.1136/rmdopen-2025-005558

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。